Effect of NR3C2 Genetic Polymorphisms on the Blood Pressure Response to Enalapril Treatment

Abstract

Aim: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated. Patients & methods: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology. Results: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003). Conclusion:NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients.

Original submitted 8 August 2013; Revision submitted 29 August 2013; Published online 23 September 2013

KEYWORDS::

• antihypertensive response
• enalapril
• NR3C2
• single nucleotide polymorphism
• SNP

Financial & competing interests disclosure

This work was supported by the National Scientific Foundation of China (No. 81273595, 81202594, 81001445), the ‘863‘ Project (No. 2012AA02A517, 2012AA02A518) and the Scientific Foundation of Hunan (No. 11K073, 10JJ4020). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

This work was supported by the National Scientific Foundation of China (No. 81273595, 81202594, 81001445), the ‘863‘ Project (No. 2012AA02A517, 2012AA02A518) and the Scientific Foundation of Hunan (No. 11K073, 10JJ4020). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.